Literature DB >> 8212841

Antigenicity of a candidate varicella-zoster virus glycoprotein subunit vaccine.

A Vafai1.   

Abstract

A 1642 bp DNA fragment, encoding the N-terminal region and 511 amino acid residues of varicella-zoster virus (VZV) glI gene, was inserted into vaccinia virus genome. The expression of recombinant vaccinia virus (designated VVTgpI-511) yielded the synthesis of a 60 kDa protein species which was processed to a secretory 76 kDa polypeptide (designated TgpI-511). The antigenicity of this protein was examined by subcutaneous inoculation of one rabbit with 100 micrograms purified TgpI-511 in the Ribi adjuvant system. The animal was boosted 3 weeks after the initial inoculation and antisera were tested 7 days after the last injection by immunoprecipitation and neutralization tests. The results showed that rabbit antibodies to TgpI-511 (RAnti-TgpI-511) were reactive with purified TgpI-511 as well as native gpI in VZV-infected cells. In addition, TgpI-511 was capable of eliciting complement-dependent VZV neutralizing antibodies. These results suggested that the purified preparation of TgpI-511 may have the potential to be used as a candidate VZV subunit vaccine.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8212841     DOI: 10.1016/0264-410x(93)90382-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Genome-wide analysis of T cell responses during acute and latent simian varicella virus infections in rhesus macaques.

Authors:  Kristen Haberthur; Aubrey Kraft; Nicole Arnold; Byung Park; Christine Meyer; Mark Asquith; Jesse Dewane; Ilhem Messaoudi
Journal:  J Virol       Date:  2013-08-28       Impact factor: 5.103

2.  Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study.

Authors:  Elchonon M Berkowitz; Graeme Moyle; Hans-Jürgen Stellbrink; Dirk Schürmann; Stephen Kegg; Matthias Stoll; Mohamed El Idrissi; Lidia Oostvogels; Thomas C Heineman
Journal:  J Infect Dis       Date:  2014-11-03       Impact factor: 5.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.